Skip to content
★ Sign in to follow
동국

동국제약 Stock: price and insider trades · South Korea

KR·Mcap ₩1.1THealth Care

No insider purchase over the last 90 days. The latest, by 브이아이피자산운용, was filed 10 Jul 2025.

동국제약: what insiders have been doing

동국제약 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). The last twelve months, up to 8 November 2026, brought 1 filing signed by 1 insider.

The flow runs one way only: 1 sale, from 1 insider, and no purchase. The totals do not cover 1 filing with an undisclosed amount.

For context, the typical company on the same exchange (median of 2,657 companies) published 7 filings over the same period, against 1 filing here. The full history, which starts in 2021, counts 2 purchases against 14 sales.

Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.

Insider Decl.
21
Thresholds
n/a
Buy Volume
€68,009
2 ops. · all time
Sell Volume
n/a
14 ops. · all time

Who traded when

BuySale
권기범1 sale
브이아이피자산운용1 buy

Analyst consensus: bullish or bearish?

Analysts rate 동국제약 Strong Buy (bullish), based on 2 analysts. Average price target: ₩31,000.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 5,875 of 26,912 companies
65.9
score / 100
Value
61
Quality
71
FCF yld2.1%
Earn yld6.2%
EV/EBITDA9.0x
ROE·
Gross mgn54%
Net mgn7.1%
Debt/EBITDA0.6x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩23,550
Analyst consensus
2 analysts
Strong buy
₩30,000Target ₩31,000(+32%)₩32,000
Income statement
Revenue₩926.9B
Gross profit₩501.6B54% margin
EBITDA₩126.4B14% margin
Net income₩66B7.1% margin
Balance sheet & cash
Market cap₩1.1T
Total debt₩76.2B
Free Cash Flow₩22.8B
Last declaration on 26 May 2026
Declarations21 total

21 of 21 declarations

About 동국제약

Dongkook Pharmaceutical is a South Korean company operating in the health and pharmaceutical sector. It is listed on the XKRX.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations